On June 24, 2024, Vico Therapeutics B.V. closed the transaction. The company raised ?11.5 million ($12.4 million) in its second and final tranche, bringing total funding raised in the transaction to ?65.8 million ($72.4 million) co-led by new investor, Seroba Life Sciences Limited and existing investor, Kurma Partners.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
161.5 EUR | -0.68% |
|
-2.06% | +1.70% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+1.70% | 5.6B | |
-13.47% | 59.76B | |
+0.63% | 58.53B | |
+17.74% | 37.2B | |
+10.40% | 30.41B | |
+9.81% | 28.4B | |
+14.79% | 20.75B | |
+14.69% | 19.41B | |
+33.62% | 17.22B | |
+69.47% | 17.16B |
- Stock Market
- Equities
- ACKB Stock
- News Ackermans & van Haaren NV
- Vico Therapeutics B.V. announced that it has received ?65.8 million in funding from a group of investors